SuperGen submits Orathecin MAA

SUPG subsidiary EuroGen Pharmaceuticals submitted an MAA to the EMEA for Orathecin rubitecan to treat pancreatic cancer in patients who have failed at least one prior chemotherapy regimen. The oral ch...